NASDAQ
Inflation, interest rates, and broader economic uncertainty have forced companies across many sectors to prioritize efficiency. In this environment, it can be particularly challenging for firms to mai...
Gilead Sciences said on Monday its experimental HIV treatment met the main goal in a late-stage trial....
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment re...
Ameriprise Financial Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 397.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Ex...
AQR Capital Management LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 32.5% in the undefined quarter, according to the company in its most recent filing with the Secur...
Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) was the target of some unusual options trading on Friday. Stock investors acquired 165,669 call options on the company. This is an increase of 1,...
Gilead Sciences and Arcus Biosciences said on Friday they would stop a late-stage study testing their experimental cancer drug combination in patients with advanced stomach and esophageal cancers afte...
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service....
Ariel Investments LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 14.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. Th...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation awards $3M in grants to close gaps in education, care, and support for people living with metastatic breast cancer....
No price data available for this timeframe.